Abstract
Two meta-analyses were conducted to quantify the benefit of combining α-IFN to 5FU in advanced colorectal cancer in terms of tumour response and survival. Analyses were based on a total of 3254 individual patient data provided by principal investigators of each trial. The meta-analysis of 5FU ± LV vs. 5FU ± LV + α-IFN combined 12 trials and 1766 patients. The meta-analysis failed to show any statistically significant difference between the two treatment groups in terms of tumour response or survival. Overall tumour response rates were 25% for patients receiving no α-IFN vs. 24% for patients receiving α-IFN (relative risk, RR = 1.02), and median survivals were 11.4 months for patients receiving no α-IFN vs. 11.5 months for patients receiving α-IFN (hazard ratio, HR = 0.95). The meta-analysis of 5FU + LV vs. 5FU + α-IFN combined 7 trials, and 1488 patients. This meta-analysis showed an advantage for 5FU + LV over 5FU + α-IFN which was statistically significant in terms of tumour response (23% vs. 18%; RR = 1.26; P = 0.042), and of a borderline significance for overall survival (HR = 1.11; P = 0.066). Metastases confined to the liver and primary rectal tumours were independent favourable prognostic factors for tumour response, whereas good performance status, metastases confined to the liver or confined to the lung, and primary tumour in the rectum were independent favourable prognostic factors for survival. We conclude that α-IFN does not increase the efficacy of 5FU or of 5FU + LV, and that 5FU + α-IFN is significantly inferior to 5FU + LV, for patients with advanced colorectal cancer. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Advanced Colorectal Cancer Meta-analysis Project (1992) Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896–903
Advanced Colorectal Cancer Meta-analysis Project (1994) Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12: 960–969
Aykan NF, Uskent N and Yaylaci M (1996) 5-fluorouracil plus interferon alpha-2b versus 5-fluorouracil plus folinic acid in advanced colorectal cancer; same efficacy but different toxicity. Ann Oncol 7: 42 (abstract 195)
Cassano A, Pozzo C and Corsi DC (1996) The role of interferon alpha-2b in the treatment with folinic acid and 5-fluorouracil of advanced colorectal cancer: a randomized study. 9th NCI-EORTC symposium on new drugs in cancer therapy; March 12–15, 1996, Amsterdam. Ann Oncol 7: 69 (abstract 234)
Colucci G, Maiello E and Gebbia V (1999) 5-Fluorouracil and Levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma. A randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group. Cancer 85: 535–545
Corfu-A Study Group (1995) Phase III randomized study of two fluorouracil combinations with either interferon alpha-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13: 921–928
Cox DR (1970). The analysis of binary data, London: United Kingdom, Methuen
Cox DR (1972) Regression models and life tables (with discussion). JR Stat Soc B 34: 187–220
Danhauser L, Gilchrist T and Friemann J (1991) Effect of recombinant interferon-alpha-2b on the plasma pharmacokinetics of fluorouracil in patients with advanced cancer. Proc Am Assoc Cancer Res 32: 1052 (abstr)
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947
Di Costanzo F, El-Taani H and Marzola M (1995) Hydroxyurea (HU), high dose folinic acid (1-FA) and 5FU vs HU, 5FU and interferon-alfa-2b (IFN) in advanced colorectal cancer (ACRC): a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Proc Am Soc Clin Oncol 14: 208 (abstract 508)
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041–1047
Dufour P, Husseini F and Dreyfus B (1996) 5-Fluorouracil versus 5-Fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study. Ann Oncol 7: 575–579
Elias L and Crissman HA (1988) Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 48: 4868–4873
Greco FA, Figlin R and York M (1996) Phase III randomized study to compare interferon alpha-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14: 2674–2681
Hill M, Norman A and Cunningham D (1995a) Royal Marsden phase III trial of fluorouracil with or without interferon Alfa-2b in advanced colorectal cancer. J Clin Oncol 13: 1297–1302
Hill M, Norman A and Cunningham D (1995b) Impact of protracted venous infusion fluorouracil with or without interferon alpha-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 13: 2317–2323
Köhne CH, Schöffski P and Wilke H (1998) Effective biomodulation by leucovorin or high-dose infusion fluorouracil given has a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16: 418–426
Kosmidis PA, Tsavaris N and Skarlos D (1996) Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 14: 2682–2687
Kreuser ED, Streit M and Kuchler T (1995) A multicenter randomized trial with the assessment of quality of life in patients with metastatic colorectal carcinoma given either folinic acid or interferon α-2b as a modulator of 5-fluorouracil. Prc Am Soc Clin Oncol 14: 202 (abstract 485)
Lindley C, Bernard B and Gavlan M (1990) Interferon-alpha increases 5-fluorouracil levels 16-fold within 1 hour: results of a phase I study. J Interferon Res 10: 9–15
Marsh JC and Rosenberg AH YALE-HIC-5698, NCI-V91-0053. Phase III comparison of 5FU/low-dose CF vs 5FU/IFN-A in patients with metastatic or recurrent colorectal adenocarcinoma. PDQ Notice.
Meta-Analysis Group In Cancer (1996) Reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: 252–258
Meta-Analysis Group In Cancer (1998a) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301–308
Meta-Analysis Group In Cancer (1998b) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537–3541
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Neefe JR and John W (1991) Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors. Semin Oncol 18: 77–82
O’Dwyer PJ, Ryan LM and Valone FH (1996) Phase III of biochemical modulation of 5-fluorouracil by IV or oral leucovorin or by interferon in advanced colorectal cancer: an ECOG/CALGB phase III trial. Proc Am Soc Clin Oncol 15: 207 (abstract 469)
Pajkos G, Izso J and Kristo K (1997) Biochemical modulation of 5-fluorouracil (FU) by leucovorin (LV) and/or interferon alpha-2a (IFN) in metastatic colorectal cancer (MCC). Anti-Cancer Treatment, Seventh International Congress, (1997 February). 6–9
Palmeri S, Danova M and Bernardo G (1998) 5-Fluorouracil plus interferon alpha-2a compared to 5-Fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study. J Cancer Res Clin Oncol 124: 191–198
Pazdur R, Ajani JA and Patt YT (1990) Phase II study of fluorouracil and recombinant interferon alpha-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 10: 2027–2031
Pensel R (1993) Advanced colon cancer (ACC): a randomized trial of fluorouracil (5FU)+folinic acid (FA) and 5FU+FA+Interferon alpha-2b (IFN). Proc Am Soc Clin Oncol 12: 203 (abstract 602)
Peto R, Pike MC and Armitage P (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient (II. Analysis and examples). Br J Cancer 35: 1–39
Piedbois P, Gimonet JF and Feuilhade F (1991) 5FU, folinic acid and alpha-2a-interferon combination in advanced gastrointestinal cancer. Proceedings of the American Society of Clinical Oncology 10: 430
Piga A, Cascinu S and Latini L (1996) A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. B J Cancer 74: 971–974
Raderer M and Scheithauer W (1995) Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. Eur J Cancer 31A: 1002–1008
Recchia F, Nuzzo A and Lalli A (1996) Randomized trial of 5-fluorouracil and high dose folinic acid with or without alpha-2b interferon in advanced colorectal cancer. Am J Clin Oncol 19: 301–304
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905–914
Seymour MT, Slevin ML and Kerr DJ (1996) Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol 14: 2280–2288
Villar-Grimalt A, Candel MT and Massuti B (1999) A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer. Br J Cancer 80: 786–791
Wadler S, Schwartz EL and Goldman M (1989) Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 12: 1769–1775
Wadler S, Wersto R and Weinberg V (1990) Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 50: 2653–2665
Weh HJ, Platz D and Braumann D (1992) Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alpha-2b: preliminary-data of a phase II study. Semin Oncol Suppl 2: 180–184
Wolmark N, Bryant J and Smith R (1998) Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst 90: 1810–1816
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Meta-Analysis Group in Cancer. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. Br J Cancer 84, 611–620 (2001). https://doi.org/10.1054/bjoc.2000.1669
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1669
Keywords
This article is cited by
-
Long-term survival benefits of adjuvant chemotherapy by decreasing incidence of tumor recurrence without delaying relapse in stage III colorectal cancer
International Journal of Colorectal Disease (2011)
-
Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer
International Journal of Clinical Oncology (2009)
-
Medical treatment of advanced colorectal carcinoma
Clinical and Translational Oncology (2004)
